Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Moodys
Merck
Cerilliant
QuintilesIMS
Chubb
Daiichi Sankyo
Fish and Richardson
Colorcon
US Department of Justice

Generated: February 21, 2018

DrugPatentWatch Database Preview

Maraviroc - Generic Drug Details

« Back to Dashboard

What are the generic sources for maraviroc and what is the scope of maraviroc patent protection?

Maraviroc
is the generic ingredient in one branded drug marketed by Viiv Hlthcare and is included in two NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Maraviroc has two hundred and forty-eight patent family members in fifty-nine countries.

There are two drug master file entries for maraviroc. Four suppliers are listed for this compound. There are two tentative approvals for this compound.
Pharmacology for maraviroc
Tentative approvals for MARAVIROC
Applicant Application No. Strength Dosage Form
➤ Sign Up➤ Sign Up150MGTABLET;ORAL
➤ Sign Up➤ Sign Up300MGTABLET;ORAL
➤ Sign Up➤ Sign Up300MGTABLET;ORAL

US Patents and Regulatory Information for maraviroc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-001 Aug 6, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-002 Aug 6, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Viiv Hlthcare SELZENTRY maraviroc SOLUTION;ORAL 208984-001 Nov 4, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-004 Nov 4, 2016 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Viiv Hlthcare SELZENTRY maraviroc SOLUTION;ORAL 208984-001 Nov 4, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-003 Nov 4, 2016 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-003 Nov 4, 2016 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Viiv Hlthcare SELZENTRY maraviroc SOLUTION;ORAL 208984-001 Nov 4, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Viiv Hlthcare SELZENTRY maraviroc SOLUTION;ORAL 208984-001 Nov 4, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Viiv Hlthcare SELZENTRY maraviroc TABLET;ORAL 022128-003 Nov 4, 2016 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for maraviroc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,503,905 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives ➤ Sign Up
7,217,714 CCR5 modulators ➤ Sign Up
6,586,431 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives ➤ Sign Up
7,041,667 CCR5 modulators ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for maraviroc

Supplementary Protection Certificates for maraviroc

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0338 Netherlands ➤ Sign Up
2008004 Lithuania ➤ Sign Up PRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010 20070918
C008/2008 Ireland ➤ Sign Up SPC008/2008: 20081105, EXPIRES: 20220917
C0007 France ➤ Sign Up PRODUCT NAME: MARAVIROC; REGISTRATION NO/DATE: EU/1/07/418/001 20070918
417 Luxembourg ➤ Sign Up 91417, EXPIRES: 20220918
2008004,C1284974 Lithuania ➤ Sign Up PRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010 20070918
C/GB08/014 United Kingdom ➤ Sign Up PRODUCT NAME: MARAVIROC, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/07/418/001 20070918; UK EU/1/04/418/002 20070918; UK EU/1/04/418/003 20070918; UK EU/1/04/418/004 20070918; UK EU/1/04/418/005 20070918; UK EU/1/04/418/006 20070918; UK EU/1/04/418/007 20070918; UK EU/1/04/418/008 20070918; UK EU/1/04/418/009 20070918; UK EU/1/04/418/010 20070918
1284974/01 Switzerland ➤ Sign Up FORMER OWNER: PFIZER INC., US
2008 Austria ➤ Sign Up PRODUCT NAME: MARAVIROC, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES; REGISTRATION NO/DATE: EU/1/07/418/001-010 20070918
6/2008 Austria ➤ Sign Up PRODUCT NAME: MARAVIROC, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
McKinsey
Deloitte
McKesson
Queensland Health
Harvard Business School
US Army
Farmers Insurance
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot